The U.S.
pharmaceutical sterility testing market size is expected to reach
USD 713.6 million by 2025, according to a new report by Grand View Research,
Inc. It is anticipated to expand at a CAGR of 11.3% over the forecast period.
Supportive government investment in healthcare industry, increasing R&D activities,
and drug launches are the key factors driving market growth.
The government is keen on bringing down healthcare
costs which is anticipated to encourage the U.S. Food and Drug Administration
(FDA) to promote fast approvals of generic pharmaceuticals. Faster approvals
drive the need for newer sterility testing methods. This is anticipated to
encourage market participants to spend more on sterility solutions and in turn,
expand the market. With increasing demand for drugs, companies are launching newer
drugs with different routes of administration, dosage, and indication. These
launches require thorough sterility testing and thus, are anticipated to drive
market growth.
On the basis of type, the U.S. pharmaceutical
sterility testing market is segmented into in-house and outsourcing. Most
market players prefer outsourcing sterility testing services, as it is
economically viable. Companies shortlist and select outsourcing firms based on
their experience, expertise, and quality of service. Hence, it is difficult for
new players to enter into this area.
Companies active in the U.S. pharmaceutical sterility
testing market are Charles River Laboratories, Pace Analytical Series LLC,
DynaLabs, Infinity, Boston Analytical, and others. Market players employ various
growth strategies such as mergers, capacity expansion, and venturing into new
regions. For instance, in April 2018, Charles River Labs completed acquisition
of MPI Research, a non-clinical Contract Research Organization (CRO) providing
detailed services to medical device and biopharmaceutical companies. This
acquisition is anticipated to expand biotechnology client base of the former
and to provide the company access to MPI’s scientific expertise and quality
services.
Browse full research report on U.S. Pharmaceutical Sterility Testing Market: https://www.grandviewresearch.com/industry-analysis/us-pharmaceutical-sterility-testing-market
Further
key findings from the report suggest:
- U.S. pharmaceutical sterility testing market was valued at USD
302.2 million in 2017 and is expected to grow lucratively over the
forecast period
- In terms of revenue, outsourcing segment is anticipated to grow at
a lucrative rate during the forecast period.
- Sterility testing segment was valued at USD 97.6 million in 2016
and is anticipated to witness swift growth over the forecast period.
Browse more reports of this category
by Grand View Research: https://www.grandviewresearch.com/industry/healthcare
Grand
View Research has segmented the U.S. pharmaceutical sterility testing market on
the basis of type, test type, end use, and sample:
U.S.
Pharmaceutical Sterility Testing by Type (Revenue, USD Million, 2014 - 2025)
- In-house
- Outsourced
U.S.
Pharmaceutical Sterility Testing by Test Type (Revenue, USD Million, 2014 -
2025)
- Sterility
Test
- Bioburden
Testing
- Bacterial
Endotoxin Test
U.S.
Pharmaceutical Sterility Testing by End Use (Revenue, USD Million, 2014 - 2025)
- Compounding
Pharmacies
- Medical
Device Companies
- Pharmaceutical
Companies
- Others
U.S.
Pharmaceutical Sterility Testing by Sample (Revenue, USD Million, 2014 - 2025)
- Sterility
Drugs
- Medical
Devices
- Biologics
& Therapies
About Grand View
Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
No comments:
Post a Comment